1800 244 735

Helpline (02) 9874 9777

Huntexil update: EMA asks for further trial

In April, the American drug regulator told NeuroSearch it would need a further large clinical trial before its Huntington’s disease symptom-control drug Huntexil would be licensed. Now the European regulator, the EMA, has said the same for European licensing.

The EMA’s advice

NeuroSearch, the Danish drug company developing Huntexil, has received advice from the European Medicines Agency (EMA) about what will be required before the company can apply for a license to sell Huntexil in Europe.

Last month, the American Food and Drug Administration (FDA) had ruled that the data from NeuroSearch’s existing trials – MermaiHD in Europe and HART in the USA – were not sufficient to prove the drug was safe and effective enough to be licensed in the USA.

The EMA’s advice echoes that of the American regulator, with both bodies calling for a further large ‘Phase III’ trial of several hundred volunteers before a license can be applied for on either continent.

NeuroSearch, Huntexil and Huntington’s

Huntexil is the brand name of ACR16, also known as pridopidine. Developed by Neurosearch, a Danish pharmacology company, Huntexil is a new possible treatment aimed at improving symptoms of Huntington’s disease.

Huntexil’s target is the movement, or ‘motor’ symptoms of HD. Unlike existing drugs, Huntexil isn’t just aimed at damping down the involuntary movements (‘chorea’ and ‘dystonia’) but at improving overall motor function including balance and voluntary control.

NeuroSearch had hoped that data from its HART and MermaiHD trials would persuade one or both regulators to consider a license, but – though both trials showed some encouraging results – neither one met its statistically pre-defined cut-off for proving the drug effective.

Back to the drawing board?

NeuroSearch appears committed to getting Huntexil licensed and has settled on a basic design for a new Phase III trial, but hasn’t yet announced where or when it’ll take place.

Licensing for drugs is often a rocky road, and the process is understandably frustrating for those waiting for new treatments. Drug regulators are cautious, and rightly so – too many drugs in the past have been licensed only to be withdrawn later when harmful or even lethal side effects emerged.

Lars Madsen, Vice President of Project and Portfolio Management at NeuroSearch, told HDBuzz “We are still committed to intensively drive pridopidine all the way to the market,” and said NeuroSearch will shortly “have a road map for our coming activities”.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more